Effects of nicotine administration on amyloid precursor protein metabolism, neural cell genesis and acquisition of spatial memory by Scerri, Charles
 
 
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 23 Issue 03 2011                                                                    
 
 
 
 
Effects of nicotine administration on amyloid 
precursor protein metabolism, neural cell genesis 
and acquisition of spatial memory 
 
Charles Scerri 
 
 
 
Abstract 
Nicotine is reported to improve learning and memory in 
experimental animals. Improved learning and memory has 
also been related to increased neural cell genesis in the 
dentate gyrus of the brain hippocampal formation. 
Stimulation of acetylcholine receptors has also been found 
to enhance the expression and secretion of amyloid 
precursor protein (APP) in various cell lines. Aberrent 
metabolism of APP generates amyloid-beta (Abeta) 
peptide which is the major pathological lesion found in the 
brains of Alzheimer’s disease (AD) patients. This paper 
will focus on the the results obtained in our laboratory on 
the effects of acute and chronic nicotine administration on 
the metabolism of APP, its role in spatial learning and 
neural cell genesis in the rat brain. 
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Introduction 
There is evidence from both clinical and preclinical 
studies that nicotine, the principal psychoactive 
component of tobacco smoke1,2, elicits improvements 
in cognitive function.3 These effects are thought to be 
related to stimulation of neurotransmitter systems 
within areas of the brain that are important for 
cognitive processing.4 As a result, nicotine and 
nicotinic drugs have been explored for their efficacy as 
putative treatments for the impaired cognitive function 
experienced by patients with conditions such as AD.5  
The subgranular zone of the dentate gyrus is one of 
the few areas of the brain in which neural cell genesis 
(neurogenesis) continues to occur into adulthood6 with 
formation of new cells arising from the proliferation of 
progenitor cells.  Increased neurogenesis can be 
produced by a variety of treatments including an 
enriched environment7, physical activity8 and 
antidepressant drugs.9 It has also been specifically 
implicated in learning tasks that involve the 
hippocampus. Training rats on a hippocampal-
dependent associative task leads to an increase in 
survival of new-born cells10 whereas preventing cell 
proliferation by administering a cytotoxic agent 
impairs performance.11  
The amyloid precursor protein is a glycoprotein that 
can exist in both membrane-bound (particulate) and 
secreted forms.12 The particulate form of the protein 
(APPp) plays a key role in the modulation of neuronal 
plasticity, synapse stabilisation and memory 
consolidation.13 The secreted (soluble) form of the 
protein, APPs, is normally generated by cleavage of 
the protein by the alpha-secretase protease enzyme at a 
site proximal to the cell membrane. This form of the 
protein exhibits both neurotrophic and neuroprotective 
properties.14 However, aberrant proteolytic cleavage of 
APP by beta- and gamma- secretases produce 
amyloid-beta (Abeta) peptide which is the major 
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component of the senile plaques found in the brains of AD 
patients.15 
 
Various studies suggest that nicotine enhances 
neuroprotective mechanisms including protecting against 
nerve growth factor deprivation16, glutamate-induced 
neurotoxicity17 and Abeta-mediated cytotoxicity.18 
Nicotine exposure increases the number of nAChRs both 
in vitro19 and in vivo20, possibly acting to attenuate the 
cognitive deficits found in AD associated with a decrease 
in the levels of acetylcholine due to the degeneration of 
cholinergic neurons. 
 
Previous studies have shown that a number of 
neurotransmitter systems, when activated, are able to 
regulate APP and Abeta metabolism. Of these, the 
cholinergic system was the mostly studied as loss of 
cholinergic receptors is an important pathological 
hallmarks in AD.21 The role of nAChR stimulation in the 
processing of APP has been reported in various cell 
lines.22,23,24 In vivo, chronic nicotine administration has 
been demonstrated to increase APP mRNA levels in the 
amygdale and hippocampus.25 The present studies used 
complimentary in vivo and in vitro experimental 
approaches to investigate the effect of chronic and acute 
nicotine treatment on APP expression in different areas of 
the rat brain and its role in the acquisition of spatial 
memory and neural cell genesis. 
 
Materials and methods 
 
1.   Effects of nicotine on APP metabolism 
For the in vivo studies, twenty-four young (6-8 weeks, 
250-300 g) and eighteen old (18 months, 560-640 g) male 
Sprague-Dawley rats (Harlan Industries, UK) were used. 
The animals from each age group were divided into three 
groups, consisting of controls ((n = 8 (young), n = 6 (old)), 
low-dose group that received 0.25 mg/kg nicotine per day 
((LDN); n = 8 (young), n = 6 (old)) and high-dose group 
that received 4.00 mg/kg nicotine per day ((HDN); n = 8 
(young), n = 6 (old)). The rats were housed, two per cage, 
at a temperature and humidity controlled environment on a 
12-h light/dark cycle and with ad lib access to food and 
water. 
 
Two-week duration osmotic minipumps (Alzet®, ALZA 
Corporation, Palo Alto, CA, USA) were filled with 
nicotine (dissolved in 0.9% saline solution) or saline as 
instructed by the manufacturer. They were implanted 
subcutaneously in the flank under halothane anaesthesia 
(5% induction, 3% maintenance) through a small incision 
on the back at the level of the shoulders. The minipumps 
were left for 13 days, after which the rats were killed by 
cervical dislocation followed by decapitation. The brain 
was removed and the cerebral cortex, striatum and 
hippocampus were dissected on ice and stored at -80oC 
prior to analysis. 
 
Thawed tissue was homogenised for 25-30 s in 10% 
lysis buffer in addition to a cocktail of protease 
inhibitors. The insoluble homogenate was removed by 
centrifugation at 1,500 r.p.m. for 5 min at 4oC. The 
supernatant was further centrifuged at 14,500 r.p.m. 
for 30 min. The resulting aqueous phase, composed 
primarily of the cytosolic fraction, and the pellet, 
containing the nuclear, mitochondrial and plasma 
membrane (particulate) fractions were both stored at –
20oC until used for APPp and APPs protein analysis.  
 
For the in vitro studies, hippocampal tissue slices 
from young (6-8 weeks) and old (19-21 month) 
Sprague-Dawley rats were used. The rats were killed 
by cervical dislocation and 400 µm thick hippocampal 
tissue slices were prepared using a McIlwain tissue 
chopper. These were added to oxygenated Kreb’s 
buffer solution in addition to a cocktail of protease 
inhibitors and incubated at 37°C. The contents were 
centrifuged at 2,500 r.p.m. for 10 min at 4°C. The 
supernatant was collected for further analysis and 
stored at -20°C until use.  
 
The protein components of the supernatant were 
precipitated by the addition of 50% trichloroacetic acid 
and the tubes incubated at 4°C for 45 min. The 
contents were then centrifuged at 14,000 r.p.m for 20 
min at 4°C to generate a protein pellet. 
 
The protein concentrations of the samples were 
determined spectrophotometrically using the method 
of Bradford.26 Samples containing 25 µg of protein 
were loaded onto 7.5% SDS-PAGE followed by 
transfer to polyvinylidene difluoride membranes. After 
blocking for one hour, the membranes were incubated 
overnight with primary antibody 22C11 (recognizing 
APP; Chemicon International, UK; 1:1500) at 4°C. 
After washing, the membranes were incubated with 
secondary antibody (goat anti-mouse IgG-horseradish 
peroxidase, Scottish Antibody Production Unit; 
1:1500) for 3-h at room temperature and protein bands 
visualised by enhanced chemiluminescence. 
 
2. Effects of nicotine on spatial learning and 
neural cell genesis 
Male Sprague-Dawley rats (Harlan Industries, UK) 
weighing 270-340 g at the start of the experiment were 
used. Rats were housed, three per cage, in a 
temperature (21°C) and humidity (50±10%) controlled 
environment on a 12 hour light/dark cycle. Rats were 
divided into 3 groups: a control group that received 
 
 
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 23 Issue 03 2011                                                                    
 
 
 
saline (Control, C), low-dose group that received 0.25 
mg/kg nicotine per day (LDN) and a high-dose group that 
received 4 mg/kg nicotine per day (HDN).   Nicotine or 
saline was administered subcutaneously via osmotic 
minipump and surgically implanted as described above. 
Following a two-day recovery period, half of the rats were 
assigned to receive spatial training (ST) and the other half 
remained in their home cage (NST; no spatial training). 
 
For the spatial learning task, rats were trained in an open 
field Morris water-maze.27 Rats were trained for 4 days to 
find an escape platform hidden below the surface of the 
water. For half of the rats the platform was located in the 
northeast quadrant and for the other half in the southwest 
quadrant.  Every day rats in the ST groups were given 2 
blocks of training composed of 4 trials each. A maximum 
search time of 120 sec was allowed for each trial. On the 
day following the last day of training, a probe trial was 
conducted to assess retention of the platform location by 
removing the platform and allowing each rat to swim for 
60 sec.  The rats were tracked using an overhead video 
camera to allow offline analysis. Performance during task 
acquisition was assessed from escape latencies (time taken 
to find the platform). For the probe trial, the computer 
calculated the percentage time spent in four equal 
quadrants of the water-maze and the number of times rats 
swam over the exact position of the platform (annulus 
crossings). 
 
Measurement of neural cell genesis was carried out 
using BrdU (Sigma, UK) which integrates into DNA 
during the S phase of DNA synthesis28. BrdU was 
dissolved in 0.9% saline and administered (50 mg/kg, i.p.) 
immediately following the last trial of the first block of 
training on days 5, 6 and 7. Rats that did not undergo 
spatial training (NST) were injected at identical time 
points.  On day 10 of the experiment, the rats were deeply 
anaesthetised with an overdose of i.p. pentobarbital 
sodium and perfused transcardially with 40 ml of saline 
followed by 140 ml of ice-cold 4% paraformaldehyde. 
Coronal sections (20 µm) were cut throughout the 
hippocampus using a cryostat. Every eighth section was 
thaw mounted on slides.  
 
The neuronal nuclear protein marker (NeuN) was used to 
help visualise the neurones within the hippocampus and 
identify the outer border of the granule cell layer. Slides 
were coded before counting to ensure objectivity. BrdU-
labelled cells were visualised using a fluorescent 
microscope (Zeiss Axioskop II). All BrdU-labelled cells 
within the granule cell layer and hilus of the DG were 
counted and the number of BrdU-positive cells for each 
subject was expressed as a mean per section.29 
 
 
Data analysis 
For APP measurement, the optical density (OD) of 
the immunoreactive bands of particulate and secreted 
forms of APP were analysed quantitatively using the 
public-domain Scion Image software (Scion 
Corporation, USA). For the in vivo studies, the mean 
OD was determined for the control groups and the 
individual values expressed as percentages. To 
determine any brain regional effects in the in vivo 
studies, a one-way ANOVA with repeated measures 
was used. Post-hoc analysis of significant effects was 
performed using Dunnett’s test. Time-course release 
profiles of APPs from control and nicotine-treated 
hippocampal tissue slices were analysed by repeated 
measures ANOVA. Profiles of APPs release from 
hippocampal tissue slice in the presence of nicotine, 
mecamylamine and EGTA were analysed using two-
way ANOVA.  
 
ANOVA with repeated measures was also used to 
determine group differences in behavioural 
performance, both during the acquisition of the spatial 
learning task and probe trial. Post-hoc analysis was 
carried out using further ANOVA or Dunnett’s 
multiple comparisons test. Group differences in BrdU-
labelled cells in the dentate gyrus were analysed using 
two-way ANOVA and post-hoc using Dunnett’s tests.  
 
The level of statistical significance was taken as 
p<0.05 and the analysis carried out using the Statistical 
Package for Social Scientists (SPSS, version 11.5). 
 
Results 
 
1. In vivo effects of nicotine on APP metabolism 
Chronic administration of nicotine increased APPp 
immunoreactivity in the hippocampus of young (F[2, 
20] = 10.18, p<0.01) but not the older rats (Figure 1). 
The nicotine infusions had no significant effects on 
APPp immunoreactivity in the striatum or cerebral 
cortex. Post-hoc tests revealed that the infusion of both 
of the doses of nicotine tested resulted in increased 
hippocampal APPp immunoreactivity (p<0.01 and 
p<0.05 respectively for the rats infused with 0.25 
mg/kg/day and 4.00 mg/kg/day). APPs 
immunoreactivity was not changed significantly by 
infusions of nicotine in any of the brain regions 
examined in both young and old rats (data not shown). 
 
2. In vitro effects of nicotine on APP metabolism 
In order to determine the time course effects of 
nicotine on APPs release, hippocampal slice 
preparations from young rats were incubated for 
periods of up to 2 h in the presence of 0 (control), 1.0 
and 10 µM nicotine. Repeated measures ANOVA 
 
 
 
Original Article 
 
 
 
 
Malta Medical Journal    Volume 23 Issue 03 2011                                                                    
 
 
 
showed that nicotine significantly increased APPs levels 
from hippocampal slices over the two hour incubation time 
(F[2, 12] = 4.76, p<0.05) (Figure 2). Post-hoc comparisons 
revealed a significant difference between the control and 
the hippocampal slice group incubated with the lowest 
(p<0.05) but not the highest nicotine concentration 
suggesting the effect of the drug was drug concentration-
related but not drug concentration-dependent (Figure 2). 
Further time-point analysis by one-way ANOVA showed 
that the greatest APPs release from hippocampal slices was 
obtained at 1 h incubation period (p<0.01). No significant 
changes in APPp were observed during the 2 h incubation 
period (data not shown). 
 
 
Figure 1: The effects of in vivo nicotine infusion on APPp 
immunoreactivity in the brain of young and old rats. APPp 
immunoreactivity in the cerebral cortex (CTX), striatum (STR) 
and hippocampus (HIPP) are presented as percentages (+SEM) 
of the mean control value (n = 6 rats per group) for animals 
chronically infused with saline (control) or nicotine at doses of 
0.25 mg/kg/day (LDN) or 4.00 mg/kg/day (HDN). Significantly 
different from control; * p<0.05; ** p<0.01. 
 
 
 
 
Figure 2: Release of APPs from hippocampal slice preparations 
in vitro in the presence of different concentrations of nicotine in 
the incubation medium up to a 2 h treatment time. The data are 
represented as a percentage change from basal level at the zero 
time point (broken line) and are expressed as mean+SEM (n = 6 
rats per group). Significantly different from control (0 µM); * 
p<0.05, ** p<0.01. 
Co-treatment of hippocampal slices with the non 
subunit-selective nicotinic receptor antagonist 
mecamylamine (10 µM) was used in order to confirm 
that the nicotine-associated increase in APPs was a 
receptor-mediated event. The antagonist significantly 
attenuated the nicotine-induced release of APPs (F[1, 
16] = 20.56, p<0.001) (Figure 3). Similarly, EGTA 
(2.5 mM), a preferential Ca2+ chelator, also showed 
similar reduction in APPs release (F[1, 16] = 8.50, p = 
0.01) (Figure 3) suggesting a possible role of calcium 
ions in the cellular process regulating nicotine-induced 
APPs release from the hippocampus. Treatment with 
mecamylamine or EGTA alone had no effect on the 
basal protein release. 
 
Figure 3: The effect of the nicotinic AChR antagonist 
mecamylamine (mec., 10 µM) or the preferential calcium 
ion chelator EGTA (2.5 mM) on nicotine-induced APPs 
release from hippocampal slice preparations as a 
percentage change from control value taken as 100%. All 
data are shown as mean+SEM (n = 6 animals per group). † 
p<0.05 from control group; * p<0.05 from nicotine-alone 
group. 
 
 
Figure 4: Nicotine-induced APPs release from hippocampal 
slice preparations generated from young (6-8 week, n = 5 
per group) and old (19-21 months, n = 5 per group) rats 
following a 1 h incubation period. The quantity of secreted 
protein was expressed as a percentage of control value 
without nicotine treatment in the same experiment (broken 
line). Data is expressed as mean+SEM.  Significantly 
different from control; * p<0.05. 
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Age-dependent effects on the release of APPs from 
hippocampal tissue was tested using hippocampal slice 
preparations derived from young and old rat brains and 
incubated in different concentrations of nicotine. Two-way 
ANOVA revealed a nicotine dose (F[2, 24] = 5.12, 
p<0.05), age (F[1, 24] = 5.72, p<0.05) and dose x age (F[2, 
24] = 4.15,  p<0.05) effect denoting that not only the 
nicotine concentration but also the age of the rats had a 
significant effect on the observed levels of APPs released 
(Figure 4). 
 
3. Effects of nicotine on spatial learning 
All treatment groups showed a general decrease in 
escape latency over training blocks and repeated measures 
ANOVA revealed significant effects of days (F[3, 60]  = 
140, p<0.001) and blocks (F[1, 20] = 54.3, p<0.001).  The 
LDN group appeared to find the platform faster than 
controls over training days 1 and 2 whereas the HDN 
group appeared to take longer to find the platform 
especially on days 2 and 4 of training (Figure 5A). There 
was a significant group x day interaction (F[6, 60] = 2.45, 
p<0.05) and further analysis of each day revealed that the 
groups only differed significantly on day 4 (F[2, 22] = 
4.37, p<0.05). Post-hoc pairwise comparisons confirmed 
that the HDN but not the LDN rats took longer than 
controls (p<0.05). Analysis of the swim speed data (Figure 
5B) revealed that there was no significant group x day 
interaction suggesting that the group difference on the 
latency measure was not due to changes in swim speed. 
 
Analysis of the percentage time spent in each quadrant 
during the probe trial suggested that while control and 
LDN rats showed a preference for the quadrant where the 
platform was located during training, the HDN rats did not 
(data not shown). Statistical analysis revealed a significant 
quadrant x treatment interaction (F[5, 60] = 3.22, p=0.05) 
and subsequent analysis of each group showed a highly 
significant quadrant effect in controls (F[2, 33] = 24.3, 
p<0.001) and LDN (F[2, 15] = 7.96, p<0.05) but not HDN 
(F[2, 12] = 1.85, p>0.1).  Analysis of the training quadrant 
only confirmed a significant effect of group (F[2, 20] = 
3.93, p<0.05) with only HDN rats spending significantly 
less time than controls in the region where the platform 
had been located (p<0.05).  Statistical analysis of the 
annulus crossings also revealed a highly significant 
quadrant by treatment interaction (F[6, 60] = 2.6, p<0.05) 
and post-hoc analyses of each group confirmed a similar 
pattern with only the HDN group failing to show a 
significant bias for the platform location. 
 
 
 
Figure 5: The effect of chronic nicotine infusions on the 
acquisition of a spatial task in the Morris water-maze.  
Escape latency values (A) in rats receiving the high dose 
nicotine infusion (HDN, n  = 5) were significantly higher 
during day 4 of training compared to that of control rats 
(Control, n = 12) and low dose nicotine (LDN, n = 6). Swim 
speed values (B) were not significantly different among the 
groups for day 4 or any other training day. Results are 
shown as mean+SEM (*p<0.05 for HDN compared to the 
control group by Dunnett’s test). Arrows on x-axis indicate 
when BrdU was administered. (C) Diagrammatic 
representation of the pool quadrants with the two possible 
platform locations (NE and SW, closed circles) and the 
eight possible start locations. 
 
 
4. Effects of nicotine neural cell genesis 
Spatial learning increased the number of BrdU-
labelled cells in the dentate gyrus in all groups relative 
to rats not receiving the task (Figure 6). 
Administration of the higher nicotine dose appeared to 
reduce BrdU-labelled cells both in trained and non-
trained animals. Statistical analysis revealed both a 
significant task (F[1, 40] = 26.87, p<0.001) and 
treatment (F[2, 40] = 20.44, p<0.001) effect but no 
interaction between the two factors (F[2, 40] = 1.19, 
p>0.1).  Post-hoc analysis of the treatment effect 
confirmed that only the high dose of nicotine reduced 
the number of cells produced compared to controls 
(p<0.05). 
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Figure 6: The effect of chronic nicotine infusions on neural cell 
genesis in the dentate gyrus in the presence (ST) and absence 
(NST) of spatial learning task. Exposure to the spatial learning 
task significantly increased the number of BrdU-labelled cells. 
High-dose nicotine (HDN, n = 5) infusion, but not the low dose 
(LDN, n = 6) reduced the number of BrdU cells in both trained 
and untrained rats compared to control (n = 12). Results are 
shown as mean+SEM (*p<0.05 compared to control by 
Dunnett’s test). Inset above: Representative black and white 
photomicrographs in a section of the dentate gyrus showing cells 
labelled for BrdU (Scale bar: 50µm). 
 
 
Discussion 
Previous studies investigating the effects of nicotine on 
APP metabolism were mostly carried out using in vitro 
methods.22,24,30,31  The present data have shown that, in vivo, 
sustained exposure to nicotine evokes an increase in 
particulate APP in the hippocampus. This response to 
nicotine was regionally-selective to the extent that it was 
not observed in the other brain regions investigated and 
age-dependent in that it was not observed in aged rats. In 
vitro studies with hippocampal tissue derived from young 
rats showed that exposure to the low (1 µM) concentration 
of nicotine increased the release of APPs, an effect that 
was attenuated by prior administration of a nicotinic 
receptor antagonist. The results suggest that acute 
stimulation of neuronal nicotinic receptors stimulates the 
release of APPs through a nicotinic-receptor mechanism 
and that, in the hippocampus, chronic exposure to nicotine 
may result in a compensatory increase in APP 
formation. This conclusion is consistent with the 
results of previous studies which have shown that 
nicotine stimulates APP expression and secretion in 
various cell lines.22,24,30  
The effects of nicotine on APPs release from 
hippocampal slices were attenuated markedly by the 
removal of Ca2+ from the incubation medium 
suggesting that the observed effects of nicotine on 
APPs release depend upon an increase in the 
intracellular free Ca2+ concentration putatively caused 
by depolarisation of the cells. Previously it was 
reported that activation of nAChRs, particularly the 
alpha7 subtype which shows high Ca2+ permeability, 
increases the intracellular Ca2+ levels leading to 
increased alpha-secretase levels via PKC and ERK 
activation.32 
In vivo effects of nicotine treatment on APPp were 
restricted to the hippocampus. The reason for this 
regionally-selective response remains unclear. 
However, the hippocampus is one of the few brain 
regions which continue to exhibit neurogenesis 
postnatally. This process persists in the rat up to 
approximately one year in age but then decreases 
markedly as the animal age further.33 The neurogenesis 
is promoted by exposure to neurotrophic factors 
including APPs.34 Hippocampal neurogenesis is also 
initially increased in the hippocampus of transgenic 
mice manipulated to over-express APP.35 This effect 
has been interpreted as compensatory response to the 
early pathology of the condition.35,36  
There is evidence that APPs may have significant 
neuroprotective and neurotrophic properties37 and it 
has been suggested that the increases in APPs release 
evoked by nicotine may mediate the proposed 
neuroprotective properties of nicotine and contribute 
to its ability to maintain cognitive function in a manner 
that might be therapeutically valuable.38 The data 
presented here, however, cast some doubt on this 
hypothesis because the effect of nicotine on APPs 
release was not observed in aged rats or hippocampal 
tissue taken from aged animals. Thus, it would seem 
that the effects of nicotine on APP processing might be 
a response observed in younger animals only. If this 
were to translate to human brain, it implies that 
nicotine may be of only limited value in the treatment 
of AD or other age-related neurodegenerative 
conditions. 
The results presented here have also shown that the 
constant infusion of the higher dose of nicotine tested 
evoked a modest impairment of the acquisition of a 
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spatial learning task and significantly impairs retention of 
spatial memory when tested with a probe trial. The effects 
of nicotine in this task were influenced by the nicotine 
dose used, the deficits only being observed in animals 
treated with the higher dose. While the reason for the 
differences in response to the two doses tested remains to 
be established, it may be significant to note that the 
infusion of nicotine at a rate of 4 mg/kg/day causes 
desensitisation of the population of neuronal nicotine 
receptors that mediate the effects of nicotine on dopamine 
release in the nucleus accumbens and dorsal striatum as 
well as noradrenaline release.39 By contrast, infusions of 
the lower dose tested (0.25 mg/kg/day) does not 
desensitise these receptors and, indeed, results in 
sensitisation of this response in animals subsequently 
challenged acutely with a single dose of nicotine.39  Thus, 
the constant infusion of nicotine at the two doses 
investigated here have already been shown to exert 
differential effects in the brain in a manner which suggests 
that they interact differentially at the diverse populations 
of neuronal nicotinic receptor that mediate the 
psychopharmacological responses to the drug. The results 
suggest that the deficit in spatial memory observed in the 
presented study may only be detected in animals in which 
many of the neuronal nicotinic receptors are desensitised 
by the drug.  
 
Many of the studies that have explored the effects of 
nicotine on learning and memory have employed 
intermittent injections of the drug administered briefly 
before each test. This data suggests that the constant 
infusion of nicotine, at a dose that causes desensitisation of 
many neuronal nicotinic receptors, has different effects on 
learning when compared with those reported previously 
using intermittent injection of the drug at doses (e.g. 0.3 
mg/kg s.c.) that generate similar plasma levels.40 Other 
studies have also shown that intermittent injections of 
nicotine stimulate the mesolimbic and nigrostriatal 
dopamine pathways and the noradrenergic projections to 
the hippocampus whereas concomitant infusion of nicotine 
blocks these responses.41 Thus, for at least three neural 
systems within the brain, the effects of infused and 
intermittently injected nicotine are quite different. 
 
The constant infusion of the higher dose of nicotine also 
inhibited BrdU incorporation into cells in the dentate gyrus 
whereas the lower dose did not have a significant effect. 
The experimental design used for this study did not 
differentiate between putative effects on cell gensis and 
survival. However, Abrous and colleagues42 also reported 
that a reduction in cell genesis in the dentate gyrus of 
animals that self-administered nicotine was only 
significant for the rats that self-administered the higher 
doses (0.04 or 0.06 mg/kg/infusion) of the drug, and did 
not occur in the subventicular zone of the hippocampus. 
By contrast, the constant infusion of nicotine into the 
mouse decreased BrdU incorporation into the granule 
cell layer of the olfactory bulb but had no significant 
effect in the dentate gyrus.43 The reason for the 
difference in the effects remains unclear, although the 
conditions of the experiment and the species studied 
were clearly different.  
 
Training in the water-maze task was associated with 
a significant increase in neural cell gensis in this area 
of the brain. Dobrossy et al44 have suggested that 
increased cell genesis in the dentate gyrus is a feature 
of the later stages of water-maze learning. However, 
Dobrossy and colleagues44 used a single 4 trial training 
block per day whereas in this study 2 x 4 trial training 
blocks per day were used. Therefore it seems 
reasonable to assume that fewer days will be required 
for the animals to reach the later phase of learning, a 
conclusion consistent with the evidence that the 
animals approached asymptotic performance by day 3 
of training. It is tempting to suggest that the deficits in 
learning, seen most clearly in the probe trial, evoked 
by the constant infusion of nicotine may be related 
directly to its effects on cell genesis in the 
hippocampus. However, this conclusion should be 
treated with some caution since nicotine suppressed 
the incorporation of BrdU in both control and maze-
trained animals. Therefore, although the absolute level 
of cell genesis in the rats trained in the maze with 
nicotine was lower than that found in saline-treated 
rats trained in the maze, cell genesis in both the saline- 
and nicotine-treated animals appeared to be elevated to 
approximately the same extent by training.  
 
In conclusion, the results reported have shown that 
nicotine administration influences the APP metabolism 
in the hippocampus of young, but not aged rats. The 
mechanisms which mediate this response have not 
been elucidated fully but appear to depend upon 
stimulation of the nAChR and the availability of 
intracellular free Ca2+. The results provide some 
support for the hypothesis that nicotinic receptor 
agonists may have some value in slowing the progress 
of AD pathology although this must be tempered by 
the evidence that the response to nicotine may be age-
dependent. Furthermore, chronic infusion of nicotine 
at a dose that is likely to cause desensitisation of many 
of the neuronal nicotinic receptors in the brain reduces 
neural cell gensis and impairs acquisition of spatial 
memory. Further studies on the effects of nicotine and 
similar compounds in animal models of AD may 
provide further insights into the potential therapeutic 
value of these compounds. 
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